Monogram’s mBōs TKA Executes World-First Autonomous Knee Surgery in 8-K

Rhea-AI Filing Summary

Monogram Technologies Inc. (Nasdaq: MGRM) filed a Form 8-K (Item 7.01 Regulation FD) to furnish a press release dated 29 July 2025 announcing completion of the world’s first fully autonomous, saw-based robotic total knee replacement. The surgery used Monogram’s proprietary mBōs™ TKA System and was performed at Krishna Shalby Hospital in Ahmedabad, India.

The company positions the procedure as proof-of-concept for closed-loop robotic orthopedic surgery, potentially accelerating its commercialization roadmap and strategic partnerships. No financial results, guidance, or transactions were disclosed; the press release is provided as Exhibit 99.1 and is deemed “furnished,” not “filed,” limiting liability under the Exchange Act.

Forward-looking-statement language flags risks around capital needs, regulatory approvals, partner dependence and litigation. Other 8-K items (7.01, 9.01) contain only exhibit references; no pro-forma financials or statements accompany the filing.

Positive

• World’s first fully autonomous robotic knee replacement validates Monogram’s mBōs TKA technology and engineering capabilities.
• Differentiates the company from competitors that offer only semi-autonomous solutions, potentially enhancing strategic value.
• Public disclosure via 8-K increases visibility and may aid in attracting partners and investors.

Negative

• Filing includes no financial metrics, making it difficult to quantify economic impact.
• Regulatory approvals (e.g., FDA) still pending; procedure conducted outside the U.S., highlighting approval risk.
• Company reiterates capital needs and profitability challenges in forward-looking statement disclaimers.

Insights

Medical Device Industry Specialist

TL;DR Breakthrough first autonomous knee surgery validates Monogram’s tech, signaling competitive edge but regulatory path still ahead.

The autonomous mBōs TKA demonstration moves Monogram from concept to clinical validation, establishing technical leadership in orthopedic robotics. Performing a fully robotic bone-resection without surgeon-held tools is a major differentiation versus semi-autonomous peers (e.g., Stryker’s Mako). The Indian site selection indicates flexibility in early clinical adoption but also underscores that FDA clearance remains outstanding. While no revenue impact is immediate, the milestone can enhance partnership negotiations and investor confidence. Overall message is materially positive, tempered by regulatory and capital risks.

Equity Research Analyst

TL;DR Milestone lifts sentiment but lacks hard numbers; impact depends on conversion to approvals and revenue.

The filing offers no financial data, yet the technological achievement may expand Monogram’s TAM narrative and justify premium multiples often assigned to disruptive med-tech. Management’s risk disclosures remind investors of ongoing cash-burn and funding needs. Until FDA authorization and reimbursement clarity are secured, valuation uplift will hinge on further clinical data and capital market access. I view the event as incrementally positive for perception, neutral for near-term fundamentals.

false 0001769759 0001769759 2025-07-26 2025-07-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): July 26, 2025

Monogram Technologies Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41707		81-3777260
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

3919 Todd Lane, Austin, TX 78744

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (512) 399-2656

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		MGRM		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

ITEM 7.01 REGULATION FD DISCLOSURE

On July 29, 2025, Monogram Technologies Inc. (the “Company”) issued a press release (the “Press Release”) announcing that the Company performed the world’s first fully autonomous saw-based robotic knee replacement surgery. The procedure utilized the Company’s mBôs™ TKA System and was performed at the Krishna Shalby Hospital in Ahmedabad India.

The foregoing disclosure is qualified in its entirety by the full text of the Press Release.

A copy of the Press Release is attached as Exhibit 99.1, and is hereby incorporated by reference into this Item 7.01. The information contained in this Current Report on Form 8-K, including Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed “filed” for any purpose, including for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing, except to the extent expressly stated in such filing.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K, including the Press Release, contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment, and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct, and you should be aware that actual events or results may differ materially from those contained in the forward- looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements.

Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in the Company’s lack of profitability and need for additional capital to grow its business; the Company’s dependence on partners to further the development of its product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory authorizations and approvals and launch of any new product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections of the Company’s latest annual and quarterly reports and other filings with the SEC.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not rely upon any forward-looking statements as predictions of future events. The Company undertakes no obligation to revise or update any forward-looking statements made in this Current Report on Form 8-K to reflect events or circumstances after the date hereof, to reflect new information or the occurrence of unanticipated events, to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, in each case, except as required by law.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits:

Exhibit No.		Description
99.1		Press Release dated July 29, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MONOGRAM TECHNOLOGIES INC.
Dated: July 29, 2025	/s/ Benjamin Sexson
	Benjamin Sexson
	Chief Executive Officer

FAQ

What did Monogram Technologies (MGRM) announce in its July 29 2025 8-K?

The company reported performing the first fully autonomous, saw-based robotic knee replacement using its mBōs TKA System.

Which system was used for the autonomous knee surgery?

Monogram’s proprietary mBōs™ TKA System executed the procedure without surgeon-held instrumentation.

Where was the autonomous knee replacement performed?

It took place at Krishna Shalby Hospital in Ahmedabad, India.

Does the 8-K include any financial results or guidance for MGRM?

No. The filing is limited to a Regulation FD disclosure; no financial statements or guidance were provided.

Why is the information in the 8-K considered "furnished" and not "filed"?

Item 7.01 materials are furnished to satisfy Regulation FD, which limits liability and prevents automatic incorporation into other SEC filings.

What key risks did Monogram highlight in the filing?

Management cited capital requirements, regulatory approvals, partner reliance, and litigation uncertainties among its forward-looking risk factors.